Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVRL1 | P37023 | 13/20 | 0.36 |
| ▸ | ACVR1 | Q04771 | 13/20 | 0.36 |
| ▸ | BMPR1A | P36894 | 11/20 | 0.36 |
| ▸ | BMPR1B | O00238 | 11/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 7/20 | 0.34 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13326635 | 0.92 | CYP11B2 (0.43) | CYP11B1CYP11B2CYP17A1CYP1A2CYP19A1 | |
| SCHEMBL13326630 | 0.82 | — | — | |
| SCHEMBL13326628 | 0.81 | CYP11B1 (0.34) | CYP11B1CYP11B2 | |
| SCHEMBL13326565 | 0.78 | CYP11B1 (0.43) | ACVRL1ACVR1BMPR1ABMPR1BCYP11B1 | |
| SCHEMBL13326613 | 0.75 | PDE5A (0.43) | ACVRL1ACVR1BMPR1ABMPR1BCYP11B1 | |
| SCHEMBL13488293 | 0.70 | ALDH1A1 (0.34) | — | |
| SCHEMBL13488300 | 0.69 | HTR2A (0.35) | — | |
| SCHEMBL11920944 | 0.69 | KDM4E (0.33) | — | |
| SCHEMBL20747274 | 0.69 | NPC1 (0.47) | CYP11B1CYP11B2CYP1A2 | |
| SCHEMBL14505901 | 0.68 | HSD17B1 (0.49) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718278-B2 | Anthrancene derivative compound and organic light-emitting device including the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2010-05-18 | — | — | US | disclosed |
| US-20080122346-A1 | ANTHRANCENE DERIVATIVE COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080122346-A1 | ANTHRANCENE DERIVATIVE COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | AR, CRY2, ANTXR2 | ACVRL1 61/4885ACVR1 95/4885BMPR1A 1497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.